Skip to content
OpenCapital
Get started

NewAmsterdam Pharma Company NAMS Q3 2025 earnings

Reported November 5, 2025 · Before market open

Revenue$348.0KMiss by $2.1M
EPS-$0.41Miss by $0.03
Revenue estimate$2.4M
EPS estimate-$0.38

Next report

Aug 5, 2026 (In 1 week)
Revenue estimate$1.9M
EPS estimate-$0.48

Financials

Q3 2025

Income statement

See full
Revenue$348.0K-98.8%
Operating income-$55.1M-121%
Net income-$72.0M-333%
EPS (diluted)-$0.61-239%

Balance sheet

See full
Cash & equivalents$538.4M+27.4%
Total debt$266.0K-47.4%
Total equity$728.1M+92.2%
Total assets$786.4M+79.1%

Cash flow

See full
Operating cash flow-$32.8M-162%
CapEx$42.0K-44.0%
Free cash flow-$32.8M-161%

Valuation & ratios

Valuation

as of 09/30/25
See full
Market cap$3.2B+114%
Enterprise value$2.67B+149%
P/S90.9×+46.4×

Profitability

See full
Operating margin-575.8%+30.6pp
Net margin-627.3%+39.6pp
FCF margin-410.1%-40.7pp

Returns & leverage

See full
Return on equity-39.9%-8.9pp
Debt / equity0×0.0×
Current ratio12.6×+2.0×

Versus estimates

Revenue

Q1 2026$3.0MBeat by $1.3MQ4 2025$32.0KMiss by $1.2M
Q3 2025$348.0KMiss by $2.1M
Q2 2025$22.4MBeat by $18.9MQ1 2025$3.2MBeat by $1.8MQ4 2024$13.2MBeat by $11.5M

Diluted EPS

Q1 2026-$0.40Beat by $0.06Q4 2025-$0.63Miss by $0.23
Q3 2025-$0.41Miss by $0.03
Q2 2025-$0.15Beat by $0.37Q1 2025-$0.49Miss by $0.04Q4 2024-$0.95Miss by $0.47

Ask the moment NewAmsterdam Pharma Company reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did NewAmsterdam Pharma Company report Q3 2025 earnings?
NewAmsterdam Pharma Company (NAMS) reported Q3 2025 earnings on November 5, 2025 before market open.
What were NewAmsterdam Pharma Company's Q3 2025 revenue and EPS?
NewAmsterdam Pharma Company reported revenue of $348.0K and eps of $-0.41 for Q3 2025.
Did NewAmsterdam Pharma Company beat estimates in Q3 2025?
Revenue missed the consensus estimate of $2.4M by $2.1M. EPS missed the consensus estimate of $-0.38 by $0.03.
How did NewAmsterdam Pharma Company's Q3 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 98.9% from $32.5M a year earlier and eps declined 127.8% from $-0.18.
Where can I find NewAmsterdam Pharma Company's Q3 2025 SEC filings?
You can read the 8-K earnings release (0001193125-25-265800) and the 10-Q periodic report (0001193125-25-265796) directly on SEC EDGAR. The filing index links above go to sec.gov.